Morgan Stanley’s Lantern Pharma LTRN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$823 Hold
601
﹤0.01% 7464
2025
Q4
$1.82K Hold
601
﹤0.01% 7264
2025
Q3
$2.61K Hold
601
﹤0.01% 7252
2025
Q2
$1.9K Hold
601
﹤0.01% 7234
2025
Q1
$2.13K Hold
601
﹤0.01% 7166
2024
Q4
$1.92K Buy
601
+1
+0.2% +$3 ﹤0.01% 7204
2024
Q3
$2.2K Hold
600
﹤0.01% 7111
2024
Q2
$2.8K Sell
600
-115
-16% -$692 ﹤0.01% 6999
2024
Q1
$6.29K Sell
715
-485
-40% -$2.59K ﹤0.01% 6835
2023
Q4
$5.14K Buy
+1,200
New +$4.23K ﹤0.01% 7001
2023
Q1
Sell
-289
Closed -$1.75K 7786
2022
Q4
$1.75K Sell
289
-5
-2% -$25 ﹤0.01% 7393
2022
Q3
$1K Sell
294
-1,100
-79% -$5.91K ﹤0.01% 7579
2022
Q2
$8K Sell
1,394
-11,507
-89% -$68.6K ﹤0.01% 7278
2022
Q1
$92K Sell
12,901
-38,440
-75% -$257K ﹤0.01% 6359
2021
Q4
$410K Buy
51,341
+3,413
+7% +$31.2K ﹤0.01% 5667
2021
Q3
$535K Sell
47,928
-4,376
-8% -$56.6K ﹤0.01% 5453
2021
Q2
$764K Buy
52,304
+1,602
+3% +$24.7K ﹤0.01% 5242
2021
Q1
$920K Buy
50,702
+22,785
+82% +$399K ﹤0.01% 4777
2020
Q4
$537K Buy
27,917
+6,533
+31% +$113K ﹤0.01% 5040
2020
Q3
$403K Buy
+21,384
New +$309K ﹤0.01% 4739

Other funds holding LTRN

Morgan Stanley's LTRN Position: Q1 2026 in Review

Morgan Stanley held its Lantern Pharma (LTRN) position steady in Q1 2026 at 601 shares worth $823. The position accounts for ﹤0.01% of the portfolio, ranked #7464.

Morgan Stanley first reported a position in LTRN in Q3 2020 and has held it in 20 quarters since. The position peaked at $920K in Q1 2021. 33 funds tracked by Wall St. Rank hold LTRN as of Q1 2026.

  • Morgan Stanley held 601 shares of Lantern Pharma worth $823 as of Q1 2026.
  • Morgan Stanley left its Lantern Pharma share count unchanged in Q1 2026.
  • Lantern Pharma made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #7464 holding.
  • Morgan Stanley first reported a position in Lantern Pharma in Q3 2020 and has held it in 20 quarters since.
  • Morgan Stanley's Lantern Pharma position peaked at $920K in Q1 2021.
  • 33 funds tracked by Wall St. Rank held Lantern Pharma as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.